Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OH2 vs Salvage Therapy in Advanced Melanoma
NCT05868707Phase 3Recruiting
- Sponsor
- Wuhan Binhui Biopharmaceutical Co., Ltd.
- Start
- Mar 2023
- Primary completion
- Mar 2026
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
A Phase 3 trial of OH2 in melanoma, sponsored by Wuhan Binhui Biopharmaceutical Co., Ltd.. Started Mar 2023; status: recruiting.
02
Drugs
OH2
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT05868707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05868707.